QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of | (I.R.S. Employer | ||||
incorporation or organization) | Identification No.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
☒ | Accelerated filer | ☐ | |||||||||
Non-accelerated filer | ☐ | Smaller reporting company | |||||||||
Emerging growth company |
(In thousands except per share data) | March 31, 2024 | September 30, 2023 | ||||||||||||
Assets | ||||||||||||||
Current assets: | ||||||||||||||
Cash and cash equivalents | $ | $ | ||||||||||||
Short-term investments | ||||||||||||||
Accounts receivable, net | ||||||||||||||
Inventories | ||||||||||||||
Prepaid expenses and other current assets | ||||||||||||||
Total current assets | $ | $ | ||||||||||||
Property and equipment, net | ||||||||||||||
Operating lease right-of-use assets | ||||||||||||||
Goodwill | ||||||||||||||
Intangible assets, net | ||||||||||||||
Restricted cash, non-current | ||||||||||||||
Other non-current assets | ||||||||||||||
Total assets | $ | $ | ||||||||||||
Liabilities and stockholders’ equity | ||||||||||||||
Current liabilities: | ||||||||||||||
Accounts payable | $ | $ | ||||||||||||
Accrued expenses | ||||||||||||||
Accrued compensation | ||||||||||||||
Current portion of operating lease liability | ||||||||||||||
Other current liabilities | ||||||||||||||
Total current liabilities | $ | $ | ||||||||||||
Operating lease liability, net of current portion | ||||||||||||||
Other non-current liabilities | ||||||||||||||
Total liabilities | $ | $ | ||||||||||||
Commitments and contingencies (Note 6) | ||||||||||||||
Stockholders’ equity | ||||||||||||||
Common stock, $ | $ | $ | ||||||||||||
Additional paid-in capital | ||||||||||||||
Accumulated other comprehensive income | ( | ( | ||||||||||||
Accumulated deficit | ( | ( | ||||||||||||
Total stockholders’ equity | $ | $ | ||||||||||||
Total liabilities and stockholders’ equity | $ | $ |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
(In thousands, except per share data) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
Revenues [1] | $ | $ | $ | $ | ||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||
Cost of revenues | $ | $ | $ | $ | ||||||||||||||||||||||
Research and development | ||||||||||||||||||||||||||
Selling, general and administrative | ||||||||||||||||||||||||||
Change in fair value of contingent considerations and holdbacks | ( | ( | ||||||||||||||||||||||||
Total operating expenses | $ | $ | $ | $ | ||||||||||||||||||||||
Loss from operations | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Interest income | ||||||||||||||||||||||||||
Interest expense | ( | ( | ||||||||||||||||||||||||
Other income (expense), net | ( | ( | ( | ( | ||||||||||||||||||||||
Loss before income taxes | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Income tax provision | ( | ( | ( | ( | ||||||||||||||||||||||
Net loss attributable to common stockholders | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Other comprehensive loss: | ||||||||||||||||||||||||||
Change in unrealized gain (loss) on investments | ( | |||||||||||||||||||||||||
Foreign currency translation adjustment | ( | |||||||||||||||||||||||||
Comprehensive loss | ( | ( | ( | ( | ||||||||||||||||||||||
Net loss per share attributable to common stockholders—basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | ||||||||||||||||||||||||||
Three months ended March 31, 2024 | ||||||||||||||||||||||||||||||||||||||
Common stock | Additional paid-in capital | Accumulated Other comprehensive loss | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||
(In thousands) | Shares | Amount | ||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2023 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
Vesting of restricted stock units | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||||||||
Exercise of stock options | — | — | — | |||||||||||||||||||||||||||||||||||
Issuance of shares under the employee stock purchase program | — | — | — | |||||||||||||||||||||||||||||||||||
Repurchases of common stock for income tax withholding | ( | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
Other comprehensive income | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
Balances as of March 31, 2024 | $ | $ | $ | ( | $ | ( | $ |
Three months ended March 31, 2023 | ||||||||||||||||||||||||||||||||||||||
Common stock | Additional paid-in capital | Accumulated Other comprehensive income | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||
(In thousands) | Shares | Amount | ||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2022 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
Vesting of restricted stock units | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||||||||
Exercise of stock options | — | — | — | |||||||||||||||||||||||||||||||||||
Issuance of shares under the employee stock purchase program | — | — | — | |||||||||||||||||||||||||||||||||||
Repurchases of common stock for income tax withholding | ( | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
Issuance of shares from business acquisition | — | — | — | |||||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
Other comprehensive income | — | — | — | — | ||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
Balances as of March 31, 2023 | $ | $ | $ | $ | ( | $ |
Six months ended March 31, 2024 | ||||||||||||||||||||||||||||||||||||||
Common stock | Additional paid-in capital | Accumulated Other comprehensive loss | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||
(In thousands) | Shares | Amount | ||||||||||||||||||||||||||||||||||||
Balances as of September 30, 2023 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
— | $ | — | $ | — | $ | — | $ | ( | $ | ( | ||||||||||||||||||||||||||||
Vesting of restricted stock units | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Exercise of stock options | — | — | — | |||||||||||||||||||||||||||||||||||
Issuance of shares under the employee stock purchase program | — | — | — | |||||||||||||||||||||||||||||||||||
Repurchases of common stock for income tax withholding | ( | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
Other comprehensive income | — | — | — | — | ||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
Balances as of March 31, 2024 | $ | $ | $ | ( | $ | ( | $ |
Six months ended March 31, 2023 | ||||||||||||||||||||||||||||||||||||||
Common stock | Additional paid-in capital | Accumulated Other comprehensive income | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||
(In thousands) | Shares | Amount | ||||||||||||||||||||||||||||||||||||
Balances as of September 30, 2022 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
Vesting of restricted stock units | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||||||||
Exercise of stock options | — | — | — | |||||||||||||||||||||||||||||||||||
Issuance of shares under the employee stock purchase plan | — | — | — | |||||||||||||||||||||||||||||||||||
Repurchases of common stock for income tax withholding | ( | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
Issuance of shares from business acquisition | ||||||||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
Other comprehensive income | — | — | — | — | ||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
Balances as of March 31, 2023 | $ | $ | $ | $ | ( | $ |
Six months ended March 31, | ||||||||||||||
(in thousands) | 2024 | 2023 | ||||||||||||
Cash flows from operating activities | ||||||||||||||
Net loss | $ | ( | $ | ( | ||||||||||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||||||||||
Depreciation and amortization | ||||||||||||||
Non-cash lease expense | ||||||||||||||
Stock-based compensation | ||||||||||||||
Change in fair value of acquisition consideration | ( | |||||||||||||
Other non-cash adjustments | ||||||||||||||
Changes in assets and liabilities: | ||||||||||||||
Accounts receivable, net | ( | |||||||||||||
Inventories | ( | |||||||||||||
Prepaid expenses and other current assets | ( | ( | ||||||||||||
Other non-current assets | ||||||||||||||
Accounts payable | ( | ( | ||||||||||||
Accrued expenses | ||||||||||||||
Accrued compensation | ( | ( | ||||||||||||
Other liabilities | ( | ( | ||||||||||||
Net cash used in operating activities | $ | ( | $ | ( | ||||||||||
Cash flows from investing activities | ||||||||||||||
Purchases of property and equipment | $ | ( | $ | ( | ||||||||||
Purchases of investments | ( | ( | ||||||||||||
Proceeds from maturity of investments | ||||||||||||||
Net cash (used in) provided by investing activities | $ | ( | $ | |||||||||||
Cash flows from financing activities | ||||||||||||||
Proceeds from exercise of stock options | $ | $ | ||||||||||||
Proceeds from issuance of common stock under employee stock purchase plan | ||||||||||||||
Repurchases of common stock for income tax withholding | ( | ( | ||||||||||||
Net cash provided by financing activities | $ | $ | ||||||||||||
Effect of exchange rates on cash, cash equivalents and restricted cash | $ | $ | ||||||||||||
Net decrease in cash, cash equivalents, and restricted cash | ( | ( | ||||||||||||
Cash, cash equivalents, and restricted cash at beginning of period | ||||||||||||||
Cash, cash equivalents, and restricted cash at end of period | $ | $ | ||||||||||||
Supplemental disclosure of cash flow information | ||||||||||||||
Income taxes paid, net of refunds | ||||||||||||||
Non-cash investing and financing activities | ||||||||||||||
Property and equipment additions included in accounts payable and accrued expenses | $ | $ | ||||||||||||
Issuance of common stock in connection with the business acquisition | $ | $ | ||||||||||||
Tenant improvement allowance capitalized in property and equipment | $ | $ |
(in thousands) | March 31, 2024 | September 30, 2023 | ||||||||||||
Cash and cash equivalents | $ | $ | ||||||||||||
Restricted cash, non-current | ||||||||||||||
Total cash, cash equivalents and restricted cash | $ | $ |
(in thousands) | Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair value | ||||||||||||||||||||||
Cash and cash equivalents | $ | $ | — | $ | — | $ | ||||||||||||||||||||
Short-term investments: | ||||||||||||||||||||||||||
U.S. government treasury bills | ( | |||||||||||||||||||||||||
Non-current assets - investment in equity securities | ||||||||||||||||||||||||||
Total | $ | $ | $ | ( | $ |
(in thousands) | Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair value | ||||||||||||||||||||||
Cash and cash equivalents | $ | $ | — | $ | — | $ | ||||||||||||||||||||
Short-term investments: | ||||||||||||||||||||||||||
Corporate bonds | ( | |||||||||||||||||||||||||
U.S. government treasury bills | ( | |||||||||||||||||||||||||
Non-current assets - investment in equity securities | ||||||||||||||||||||||||||
Total | $ | $ | $ | ( | $ |
(in thousands) | Level 1 | Level 2 | Level 3 | Fair value | ||||||||||||||||||||||
Assets | ||||||||||||||||||||||||||
Money market funds | $ | $ | $ | $ | ||||||||||||||||||||||
U.S. government treasury bills | ||||||||||||||||||||||||||
Non-current assets - investment in equity securities | ||||||||||||||||||||||||||
Total | $ | $ | $ | $ | ||||||||||||||||||||||
Total financial liabilities | $ | $ | $ | $ |
(in thousands) | Level 1 | Level 2 | Level 3 | Fair value | ||||||||||||||||||||||
Assets | ||||||||||||||||||||||||||
Money market funds | $ | $ | $ | $ | ||||||||||||||||||||||
Corporate bonds | ||||||||||||||||||||||||||
U.S. government treasury bills | ||||||||||||||||||||||||||
Non-current assets - investment in equity securities | ||||||||||||||||||||||||||
Total financial assets | $ | $ | $ | $ | ||||||||||||||||||||||
Total financial liabilities | $ | $ | $ | $ |
(in thousands) | Equity investments | Total | ||||||||||||
Balance as of September 30, 2023 | $ | $ | ||||||||||||
Change in fair value | ||||||||||||||
Balance as of March 31, 2024 | $ | $ |
(in thousands) | March 31, 2024 | September 30, 2023 | ||||||||||||
Raw materials | $ | $ | ||||||||||||
Work-in-process | ||||||||||||||
Finished goods | ||||||||||||||
$ | $ |
(in thousands) | March 31, 2024 | September 30, 2023 | ||||||||||||
Laboratory equipment | $ | $ | ||||||||||||
Furniture, fixtures and other equipment | ||||||||||||||
Vehicles | ||||||||||||||
Computer equipment | ||||||||||||||
Computer software | ||||||||||||||
Leasehold improvements | ||||||||||||||
Construction in progress | ||||||||||||||
$ | $ | |||||||||||||
Less: Accumulated depreciation | ( | ( | ||||||||||||
$ | $ |
(in thousands) | March 31, 2024 | September 30, 2023 | ||||||||||||
Income and other taxes payable | $ | $ | ||||||||||||
Contract liabilities | ||||||||||||||
Other current liabilities | ||||||||||||||
$ | $ |
(in thousands) | March 31, 2024 | September 30, 2023 | ||||||||||||
Balance at beginning of period/year | $ | $ | ||||||||||||
Balance at end of period/year | $ | $ |
March 31, 2024 | ||||||||||||||||||||||||||
(in thousands, except for years) | Weighted average Amortization period in years | Gross carrying amount | Accumulated amortization | Net book value | ||||||||||||||||||||||
Developed Technology | $ | $ | ( | $ | ||||||||||||||||||||||
Customer Relationships | ( | |||||||||||||||||||||||||
Tradenames & Trademarks | ( | |||||||||||||||||||||||||
Total finite-lived intangible assets | $ | $ | ( | $ |
September 30, 2023 | ||||||||||||||||||||||||||
(in thousands, except for years) | Weighted average Amortization period in years | Gross carrying amount | Accumulated amortization | Net book value | ||||||||||||||||||||||
Developed Technology | $ | $ | ( | $ | ||||||||||||||||||||||
Customer Relationships | ( | |||||||||||||||||||||||||
Tradenames & Trademarks | $ | $ | ( | $ | ||||||||||||||||||||||
Total finite-lived intangible assets | $ | $ | ( | $ |
(in thousands) | March 31, 2024 | |||||||
Assets: | ||||||||
Operating lease right-of-use asset | $ | |||||||
Current liabilities: | ||||||||
Current portion of operating lease liabilities | $ | |||||||
Noncurrent liabilities: | ||||||||
Operating lease liabilities, net of current portion | $ |
(in thousands) | Operating leases | |||||||
Years ending September 30: | ||||||||
Remainder of 2024 | $ | |||||||
2025 | ||||||||
2026 | ||||||||
2027 | ||||||||
2028 | ||||||||
Thereafter | ||||||||
Total minimum lease payments | $ | |||||||
Less: imputed interest | ( | |||||||
Total operating lease liabilities | $ | |||||||
Less: current portion | ( | |||||||
Operating lease liabilities, net of current portion | $ |
(in thousands, except per share data) | Shares | Weighted average grant date fair value per share | ||||||||||||
Nonvested shares at September 30, 2023 | $ | |||||||||||||
Granted | ||||||||||||||
Vested/Issued | ( | |||||||||||||
Forfeited | ( | |||||||||||||
Nonvested shares at March 31, 2024 | $ |
(in thousands, except per share data) | Shares | Weighted average grant date fair value per share | ||||||||||||
Nonvested shares at September 30, 2023 | $ | |||||||||||||
Granted | ||||||||||||||
Vested/Issued | ( | |||||||||||||
Forfeited | ( | |||||||||||||
Nonvested shares at March 31, 2024 | $ |
(in thousands, except per share data) | Shares | Weighted average exercise price per share | Weighted average remaining contractual term (years) | Aggregate intrinsic value | ||||||||||||||||||||||
Outstanding at September 30, 2023 | $ | $ | ||||||||||||||||||||||||
Forfeited | ( | — | — | |||||||||||||||||||||||
Exercised | ( | — | ||||||||||||||||||||||||
Outstanding at March 31, 2024 | $ | $ | ||||||||||||||||||||||||
Nonvested at March 31, 2024 | ||||||||||||||||||||||||||
Exercisable at March 31, 2024 | $ | $ |
(in thousands, except per share data) | Shares | Weighted average exercise price per share | Weighted average remaining contractual term (years) | Aggregate intrinsic value | ||||||||||||||||||||||
Outstanding at September 30, 2023 | $ | $ | ||||||||||||||||||||||||
Nonvested at September 30, 2023 | $ | $ | ||||||||||||||||||||||||
Exercisable at September 30, 2023 | ||||||||||||||||||||||||||
Forfeited | ( | $ | — | $ | — | |||||||||||||||||||||
Exercisable at March 31, 2024 | $ | $ | ||||||||||||||||||||||||
Nonvested at March 31, 2024 | ||||||||||||||||||||||||||
Outstanding at March 31, 2024 | $ | $ |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
(in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
Cost of revenues | $ | $ | $ | $ | ||||||||||||||||||||||
Research and development | ||||||||||||||||||||||||||
Selling, general and administrative | ( | |||||||||||||||||||||||||
Total stock-based compensation | $ | $ | $ | $ |
(In thousands) | Shares available | |||||||
Outstanding at September 30, 2023 | ||||||||
Additional shares authorized | ||||||||
Shares issued during the period | ( | |||||||
Outstanding at March 31, 2024 |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
(in thousands, except per share data) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
Numerator: | ||||||||||||||||||||||||||
Net loss attributable to common stockholders | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Denominator: | ||||||||||||||||||||||||||
Weighted average shares used in computing net loss per share, basic and diluted | ||||||||||||||||||||||||||
Net loss per share attributable to common stockholders, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( |
Three and six months ended | ||||||||||||||
March 31, | ||||||||||||||
(in thousands) | 2024 | 2023 | ||||||||||||
Shares subject to options (including performance options) to purchase common stock | ||||||||||||||
Unvested restricted stock units and performance stock units | ||||||||||||||
Shares subject to employee stock purchase plan | ||||||||||||||
Total |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
(in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
Americas | $ | $ | $ | $ | ||||||||||||||||||||||
EMEA | ||||||||||||||||||||||||||
APAC | ||||||||||||||||||||||||||
Total | $ | $ | $ | $ |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
(in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
Synthetic genes | $ | $ | $ | $ | ||||||||||||||||||||||
Oligo pools | ||||||||||||||||||||||||||
DNA libraries | ||||||||||||||||||||||||||
Antibody discovery | ||||||||||||||||||||||||||
NGS tools | ||||||||||||||||||||||||||
Total | $ | $ | $ | $ |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
(in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
Industrial chemicals/materials | $ | $ | $ | $ | ||||||||||||||||||||||
Academic research | ||||||||||||||||||||||||||
Healthcare | ||||||||||||||||||||||||||
Food/agricultural | ||||||||||||||||||||||||||
Total | $ | $ | $ | $ |
Three months ended | Six months ended | |||||||||||||||||||||||||
March 31, | March 31, | |||||||||||||||||||||||||
(in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
Revenues | $ | 75,302 | $ | 60,180 | $ | 146,800 | $ | 114,423 | ||||||||||||||||||
Loss from operations | (48,889) | (61,637) | (95,866) | (106,267) | ||||||||||||||||||||||
Net loss attributable to common stockholders | (45,492) | (59,156) | (88,500) | (100,980) |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | % | 2023 | % | 2024 | % | 2023 | % | ||||||||||||||||||||||||||||||||||||||||||
Americas | $ | 45,873 | 61 | % | $ | 34,925 | 58 | % | $ | 89,832 | 61 | % | $ | 68,571 | 60 | % | ||||||||||||||||||||||||||||||||||
EMEA | 22,263 | 30 | % | 18,780 | 31 | % | 43,483 | 30 | % | 35,111 | 31 | % | ||||||||||||||||||||||||||||||||||||||
APAC | 7,166 | 9 | % | 6,475 | 11 | % | 13,485 | 9 | % | 10,741 | 9 | % | ||||||||||||||||||||||||||||||||||||||
Total revenues | $ | 75,302 | 100 | % | $ | 60,180 | 100 | % | $ | 146,800 | 100 | % | $ | 114,423 | 100 | % |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | % | 2023 | % | 2024 | % | 2023 | % | ||||||||||||||||||||||||||||||||||||||||||
Synthetic genes | $ | 22,356 | 29 | % | $ | 18,011 | 30 | % | $ | 42,083 | 28 | % | $ | 34,186 | 30 | % | ||||||||||||||||||||||||||||||||||
Oligo pools | 3,940 | 6 | % | 3,315 | 5 | % | 8,129 | 6 | % | 7,015 | 6 | % | ||||||||||||||||||||||||||||||||||||||
DNA libraries | 3,531 | 5 | % | 2,826 | 5 | % | 6,470 | 4 | % | 4,662 | 4 | % | ||||||||||||||||||||||||||||||||||||||
Antibody discovery | 4,701 | 6 | % | 7,034 | 12 | % | 9,927 | 7 | % | 15,205 | 13 | % | ||||||||||||||||||||||||||||||||||||||
NGS tools | 40,774 | 54 | % | 28,994 | 48 | % | 80,191 | 55 | % | 53,355 | 47 | % | ||||||||||||||||||||||||||||||||||||||
Total revenues | $ | 75,302 | 100 | % | $ | 60,180 | 100 | % | $ | 146,800 | 100 | % | $ | 114,423 | 100 | % |
Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | % | 2023 | % | 2024 | % | 2023 | % | ||||||||||||||||||||||||||||||||||||||||||
Industrial chemicals/materials | $ | 20,264 | 27 | % | $ | 14,410 | 24 | % | $ | 36,542 | 25 | % | $ | 27,985 | 24 | % | ||||||||||||||||||||||||||||||||||
Academic research | 13,722 | 18 | % | 11,120 | 19 | % | 27,495 | 18 | % | 21,135 | 19 | % | ||||||||||||||||||||||||||||||||||||||
Healthcare | 40,934 | 54 | % | 33,764 | 56 | % | 81,815 | 56 | % | 63,777 | 56 | % | ||||||||||||||||||||||||||||||||||||||
Food/agriculture | 382 | 1 | % | 886 | 1 | % | 948 | 1 | % | 1,526 | 1 | % | ||||||||||||||||||||||||||||||||||||||
Total revenues | $ | 75,302 | 100 | % | $ | 60,180 | 100 | % | $ | 146,800 | 100 | % | $ | 114,423 | 100 | % | ||||||||||||||||||||||||||||||||||
Three months ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
March 31, | December 31, | September 30, | June 30, | March 31, | December 31, | September 30, | June 30, | |||||||||||||||||||||||||||||||||||||||||||
(in thousands) | 2024 | 2023 | 2023 | 2023 | 2023 | 2022 | 2022 | 2022 | ||||||||||||||||||||||||||||||||||||||||||
Number of genes shipped | 193 | 171 | 177 | 171 | 152 | 134 | 146 | 163 | ||||||||||||||||||||||||||||||||||||||||||
Number of shipments | 20 | 18 | 17 | 17 | 15 | 14(1) | 20 | 15 |
Three months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Revenues | $ | 75,302 | $ | 60,180 | $ | 15,122 | 25 | % |
Three months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Cost of revenues | $ | 44,420 | $ | 41,669 | $ | 2,751 | 7 | % |
Three months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Research and development | $ | 24,149 | $ | 27,379 | $ | (3,230) | (12) | % |
Three months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Selling, general and administrative | $ | 55,622 | $ | 53,965 | $ | 1,657 | 3 | % |
Three months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Change in fair value of contingent consideration and holdbacks | $ | — | $ | (1,196) | $ | 1,196 | (100) | % |
Three months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Interest income | $ | 3,941 | $ | 3,464 | $ | 477 | 14 | % | ||||||||||||||||||
Interest expense | — | (2) | 2 | (100) | % | |||||||||||||||||||||
Other expense | (199) | (305) | 106 | (35) | % | |||||||||||||||||||||
Total interest and other income (expense), net | $ | 3,742 | $ | 3,157 | $ | 585 | 19 | % |
Three months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Income tax provision | $ | (345) | $ | (676) | $ | 331 | (49) | % |
Six months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Revenues | $ | 146,800 | $ | 114,423 | $ | 32,377 | 28 | % |
Six months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Cost of revenues | $ | 86,955 | $ | 71,111 | $ | 15,844 | 22 | % |
Six months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Research and development | $ | 47,249 | $ | 58,621 | $ | (11,372) | (19) | % |
Six months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Selling, general and administrative | $ | 108,462 | $ | 96,289 | $ | 12,173 | 13 | % |
Six months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Change in fair value of contingent consideration and holdbacks | $ | — | $ | (5,331) | $ | 5,331 | (100) | % |
Six months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Interest income | $ | 8,061 | $ | 6,504 | $ | 1,557 | 24 | % | ||||||||||||||||||
Interest expense | — | (3) | 3 | (100) | % | |||||||||||||||||||||
Other expense | (230) | (462) | 232 | (50) | % | |||||||||||||||||||||
Total interest and other income (expense), net | $ | 7,831 | $ | 6,039 | $ | 1,792 | 30 | % |
Six months ended March 31, | ||||||||||||||||||||||||||
(in thousands, except percentages) | 2024 | 2023 | Change | % | ||||||||||||||||||||||
Income tax provision | $ | (465) | $ | (752) | $ | 287 | (38) | % |
Six months ended March 31, | ||||||||||||||
(in thousands) | 2024 | 2023 | ||||||||||||
Net cash used in operating activities | $ | (42,396) | $ | (98,358) | ||||||||||
Net cash provided by (used in) investing activities | (1,075) | 34,189 | ||||||||||||
Net cash provided by financing activities | 355 | 1,130 |
Exhibit Number | Description | Filed / Furnished / Incorporated from Form | ||||||||||||
31.1 | Filed herewith | |||||||||||||
31.2 | Filed herewith | |||||||||||||
32.1† | Furnished herewith | |||||||||||||
32.2† | Furnished herewith | |||||||||||||
10.1* | Filed herewith | |||||||||||||
101 | The following materials from Twist Bioscience Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Stockholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Unaudited Condensed Consolidated Financial Statements, tagged as blocks of text. | Filed herewith | ||||||||||||
104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL (included in Exhibit 101). | Filed herewith |
* | Management contract or compensatory plan or arrangement. | ||||
† | The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Twist Bioscience Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, regardless of any general incorporation language contained in any filing. |
May 2, 2024 | Twist Bioscience Corporation | |||||||
By: | /s/ Adam Laponis | |||||||
Adam Laponis | ||||||||
Chief Financial Officer | ||||||||
(Authorized officer) |
/s/ Emily M. Leproust | |||||
Emily M. Leproust | |||||
Chief Executive Officer | |||||
(Principal Executive Officer) |
/s/ Adam Laponis | |||||
Adam Laponis | |||||
Chief Financial Officer |
/s/ Emily M. Leproust | |||||
Emily M. Leproust | |||||
Chief Executive Officer | |||||
(Principal Executive Officer) |
/s/ Adam Laponis | |||||
Adam Laponis | |||||
Chief Financial Officer |
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares shares in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Common stock, par value (in usd per share) | $ 0.00001 | $ 0.00001 |
Common stock, authorized (in shares) | 100,000 | 100,000 |
Common stock, issued (in shares) | 58,162 | 57,557 |
Common stock, outstanding (in shares) | 58,162 | 57,557 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Statement of Comprehensive Income [Abstract] | ||||||
Revenues | [1] | $ 75,302 | $ 60,180 | $ 146,800 | $ 114,423 | |
Operating expenses: | ||||||
Cost of revenues | 44,420 | 41,669 | 86,955 | 71,111 | ||
Research and development | 24,149 | 27,379 | 47,249 | 58,621 | ||
Selling, general and administrative | 55,622 | 53,965 | 108,462 | 96,289 | ||
Change in fair value of contingent considerations and holdbacks | 0 | (1,196) | 0 | (5,331) | ||
Total operating expenses | 124,191 | 121,817 | 242,666 | 220,690 | ||
Loss from operations | (48,889) | (61,637) | (95,866) | (106,267) | ||
Interest income | 3,941 | 3,464 | 8,061 | 6,504 | ||
Interest expense | 0 | (2) | 0 | (3) | ||
Other income (expense), net | (199) | (305) | (230) | (462) | ||
Loss before income taxes | (45,147) | (58,480) | (88,035) | (100,228) | ||
Income tax provision | (345) | (676) | (465) | (752) | ||
Net loss attributable to common stockholders | (45,492) | (59,156) | (88,500) | (100,980) | ||
Other comprehensive loss: | ||||||
Change in unrealized gain (loss) on investments | (57) | 647 | 77 | 1,516 | ||
Foreign currency translation adjustment | (38) | 73 | 19 | 438 | ||
Comprehensive loss | $ (45,587) | $ (58,436) | $ (88,404) | $ (99,026) | ||
Net loss per share attributable to common stockholders—basic (in usd per share) | $ (0.79) | $ (1.04) | $ (1.54) | $ (1.78) | ||
Net loss per share attributable to common stockholders—diluted (in usd per share) | $ (0.79) | $ (1.04) | $ (1.54) | $ (1.78) | ||
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares) | 57,779 | 56,777 | 57,637 | 56,608 | ||
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares) | 57,779 | 56,777 | 57,637 | 56,608 | ||
|
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Parenthetical) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Revenue | [1] | $ 75,302 | $ 60,180 | $ 146,800 | $ 114,423 | |
Related Party | ||||||
Revenue | $ 3,200 | $ 2,200 | $ 5,600 | $ 2,600 | ||
|
The Company |
6 Months Ended |
---|---|
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
The Company | The Company Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology company that has developed a disruptive DNA synthesis platform. DNA is used in many applications across different industries: industrial chemicals/materials, academic, healthcare and food/agriculture. The Company’s fiscal year ends on September 30. The core of the Company’s platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. The Company has combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables the Company to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost than its competitors. The Company is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sample preparation, and antibody libraries for drug discovery and development. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in this industry. These risks include, but are not limited to, the uncertainty of availability of additional financing, market acceptance of its products, the ability to retain and attract new customers, and the uncertainty of achieving future profitability. The Company has generated net losses in all periods since its inception. As of March 31, 2024, the Company had an accumulated deficit of $1,121.7 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing. As of March 31, 2024, the Company had cash and cash equivalents and short-term investments of $293.3 million, which the management believes will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements. However, if the Company needs to obtain additional financing to fund operations beyond this period, there can be no assurance that it will be successful in raising additional financing on terms which are acceptable to the Company. If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.
|
Summary of significant accounting policies |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of significant accounting policies | Summary of significant accounting policies Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2023 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 21, 2023. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2023 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and six months ended March 31, 2024 are not necessarily indicative of the results expected for the full year ending September 30, 2024 or any interim period. The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation. The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows:
Restricted cash represents cash held at financial institutions that are pledged as collateral for stand-by letters of credit for lease commitments and is included in non-current assets. Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K other than disclosed below. Allowance for Credit Losses The Company maintains an allowance for credit losses for expected uncollectible accounts receivable and contract assets, which is recorded as an offset to accounts receivable or contract assets and provisions for credit losses are recorded in general and administrative expense in the consolidated statements of income. Under the application of Accounting Standards Codification (“ASC”) Topic 326-20, Financial Instruments—Credit Losses (“ASC 326”), the allowance for current expected credit losses is based on a review of customer accounts and considers historical credit loss information that is adjusted for current economic and business conditions and anticipated future economic events that may impact collectability. In developing its expected credit loss estimate, the Company evaluated the appropriate grouping of accounts receivable and contract assets based upon its evaluation of risk characteristics, including consideration of region and industries of the customers. The allowance for credit losses is reviewed on a quarterly basis to assess the adequacy of the allowance. Allowance for credit losses was $0.7 million as of March 31, 2024. Short-term investments The Company invests in various types of securities, including United States government, commercial paper, and corporate debt securities. The Company classifies its investments as available-for-sale and records them at fair value based upon market prices at period end. For available-for-sale debt securities in an unrealized loss position, the Company evaluates whether a current expected credit loss exists based on available information relevant to the credit rating of the security, current economic conditions and reasonable and supportable forecasts. The allowance for credit loss is recorded in other income (expense), net, on the consolidated statements of income, not to exceed the amount of the unrealized loss. Any excess unrealized loss other than the credit loss is recognized in accumulated other comprehensive income or loss in the stockholders' equity section of the consolidated balance sheets. The cost of securities sold is based on the specific identification method and realized gains and losses are included in other income (expense), net. Dividend and interest income are recognized when earned. The Company may sell these securities at any time for use in current operations. There was no allowance for credit losses relating to the short-term investments recognized as of March 31, 2024. Revenue The Company had contract assets of $2.7 million and contract liabilities of $2.5 million as of March 31, 2024. The Company had contract assets of $2.8 million and contract liabilities of $3.0 million as of September 30, 2023. For the three and six months ended March 31, 2024, the Company recognized revenue of $0.9 million and $2.2 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period. For the three and six months ended March 31, 2023, the Company recognized revenue of $1.4 million and $2.7 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period. In addition, for all periods presented, there was no revenue recognized in a reporting period from performance obligations satisfied in previous periods. The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of March 31, 2024 was $5.9 million. The Company expects to recognize revenue over the next twelve months relating to performance obligations unsatisfied as of March 31, 2024. Based on the nature of the Company's contracts with customers, which are recognized over a term of less than 12 months, the Company has elected to use the practical expedient whereby costs to obtain a contract are expensed as they are incurred. The Company states its revenues net of any taxes collected from customers that are required to be remitted to various government agencies. The amount of taxes collected from customers and payable to governmental entities is included on the balance sheet as part of “Accrued expenses and other current liabilities.” Recent accounting pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s ASC. The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations. Recent accounting pronouncements adopted In June 2016, FASB issued ASU No. 2016-13 “Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments” and has since modified the standard with several ASUs (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets. The ASU replaced previous incurred loss impairment guidance and established a single expected credit losses allowance framework for financial assets carried at amortized cost. It also eliminated the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses. On October 1, 2023, the Company adopted this standard using a modified retrospective approach, which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption and, accordingly, recorded a net increase of $0.1 million to accumulated deficit as of the beginning of fiscal 2024. In connection with the adoption of Topic 326, the Company made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. Recently issued accounting pronouncement not yet adopted In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740)". The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The standard is not expected to have a material impact to the Company's condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-08 "Segment Reporting (Topic 280)". The amendments in this ASU improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The standard is not expected to have a material impact to the Company's condensed consolidated financial statements. The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.
|
Fair value measurement |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value measurement | Fair value measurement The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its assessment of fair value. The following table sets forth the cash and cash equivalents, short-term investments and equity securities as of March 31, 2024:
The following table sets forth the cash and cash equivalents, short-term investments and equity securities as of September 30, 2023:
As of March 31, 2024, financial assets and liabilities measured and recognized at fair value are as follows:
As of September 30, 2023, financial assets and liabilities measured and recognized at fair value are as follows:
Contractual maturities of all the investments, as of March 31, 2024, were less than 12 months. The Company does not intend to sell the money market funds and short-term investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis. The Company's short-term investments have been in a continuous unrealized loss position for less than 12 months. Accrued interest receivable balances included in the prepaid expenses and other current assets within the condensed consolidated balance sheets were $1.1 million and $1.2 million as of March 31, 2024 and September 30, 2023, respectively. As of March 31, 2024, the gross unrealized losses on short-term investments are related to market interest rate changes and not attributable to credit. During 2021 and as amended in 2022, the Company entered into convertible promissory note agreements with a privately held company (“Borrower”) pursuant to which the Company agreed to loan to the Borrower $3.5 million in a series of loan installments, evidenced by a convertible promissory note having a maturity date of May 1, 2023 (“Convertible Note”). The Convertible Note included an option to convert the Convertible Note into the Borrower’s equity at the Borrower’s next round of equity financing, and accrued interest at a rate of 4% per annum. In April 2023, the Company exercised the option and the Borrower issued to the Company ordinary shares which represent a 15% equity interest. As of March 31, 2024, the Company’s equity investments were categorized as Level 3 within the fair value hierarchy. The equity investment held by the Company is a VIE, but the Company is not the primary beneficiary. The Company does not have the power to direct the activities that most significantly impact the economic performance of the investee. The Company’s maximum exposure to loss from this VIE consist of an equity investment of $3.7 million. Equity investments held by the Company lack readily determinable fair values and therefore the securities are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar equity securities of the same issuer. The Company reviews the carrying value of its equity investments for impairment whenever events or changes in business circumstances indicate the carrying amount of such asset may not be fully recoverable. Impairments, if any, are based on the excess of the carrying amount over the recoverable amount of the asset. There were no such impairments during the three months ended March 31, 2024 and March 31, 2023. As of March 31, 2024 and September 30, 2023, there were no financial liabilities categorized as level 3 within the fair value hierarchy. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. The following table provides a reconciliation of beginning and ending balances of the Level 3 financial assets during the three months ended March 31, 2024:
|
Balance sheet components |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Related Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet components | Balance sheet components Inventories consist of the following:
There is no consigned inventory balance as of March 31, 2024 and September 30, 2023. Property and Equipment, net consists of the following:
As of March 31, 2024, the construction in progress mainly represents equipment costs and software development costs. For the three and six months ended March 31, 2024, the total depreciation expense was $7.0 million and $13.9 million, respectively. For the three and six months ended March 31, 2023 the total depreciation expense was $5.7 million and $9.9 million, respectively. The other current liabilities consist of the following:
|
Goodwill and intangible assets |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and intangible assets | Goodwill and intangible assets There were no changes to the carrying value of goodwill during the six months ended March 31, 2024. The goodwill balance is presented below:
The intangible assets balances are presented below:
Total amortization expense related to finite-lived intangible assets was $1.3 million for the three months ended March 31, 2024 and $1.3 million for the three months ended March 31, 2023. Total amortization expense related to finite-lived intangible assets was $2.6 million for the six months ended March 31, 2024 and $2.7 million for the six months ended March 31, 2023.
|
Commitments and contingencies |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and contingencies | Commitments and contingencies Legal proceedings The Company may be subject to litigation, claims and disputes in the ordinary course of business. There is an inherent risk in any litigation or dispute and no assurance can be given as to the outcome of any claims. Securities Class Action On December 12, 2022, a putative securities class action lawsuit captioned Peters v. Twist Bioscience Corporation, et al., Case No. 22-cv-08168 (N.D. Cal.) (“Securities Class Action”) was filed in federal court in the Northern District of California (“Court”) against the Company, its Chief Executive Officer, and its Chief Financial Officer (the “Defendants”) alleging violations of federal securities laws. The Securities Class Action’s claims are based in large part on allegations made in a report issued on November 15, 2022 by Scorpion Capital (“Scorpion Report”) concerning, among other things, the Company’s DNA chip technology and accounting practices. The initial complaint filed in the Securities Class Action alleges that various statements that the defendants made between December 13, 2019 and November 14, 2022 were materially false and misleading in light of the allegations in the Scorpion Report. The plaintiff who initiated the lawsuit sought to represent a class of shareholders who acquired shares of the Company’s common stock between December 13, 2019 and November 14, 2022 and sought damages as well as certain other costs. On July 28, 2023, the Court appointed a new plaintiff, not the original plaintiff who filed the case, as lead plaintiff in the case and appointed a new law firm as lead counsel. On October 11, 2023, the lead plaintiff filed an amended complaint. The amended complaint is purportedly brought on behalf of all persons other than the Defendants who acquired the Company’s securities between December 20, 2018 and November 15, 2022. The amended complaint alleges that certain statements regarding, among other things, the Company’s DNA products and accounting practices were false and misleading. This case remains in the preliminary stage. Given the inherent uncertainty of litigation and the legal standards that must be met, including class certification and success on the merits, the Company cannot express an opinion on the likelihood of an unfavorable outcome or on the amount or range of any potential loss. The Company and the other defendants intend to vigorously defend themselves against the claims asserted against them, and filed a motion to dismiss the amended complaint on December 6, 2023, which the Court has taken under submission. Derivative Action On September 25, 2023, a shareholder derivative suit captioned Shumacher vs. Leproust et al., No. 1:23-cv-01048-UNA, was filed in the United States District Court for the District of Delaware against directors of the Company and an employee (the “Derivative Action”). The suit is based on substantially the same allegations in the Securities Class Action and seeks to recover, on behalf of the Company, damages to the Company arising from, among other things, the Securities Class Action. On November 13, 2023, the parties to the Derivative Action entered into a stipulation staying the Derivative Action pending resolution of the anticipated motion to dismiss the defendants have filed in the Securities Class Action. Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. From time to time, the Company has entered into indemnification agreements with its directors and officers that requires it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by law. The Company also has directors’ and officers’ insurance. Leases The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2044. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, as well as payments for common-area-maintenance and administrative services. The Company often receives customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases. Leases are classified as operating or financing at commencement. The Company does not have any material financing leases. Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants. Supplemental balance sheet information related to the Company’s operating leases as of March 31, 2024 is as follows:
Future minimum lease payments under all non-cancelable operating leases that have commenced as of March 31, 2024 are as follows:
The statement of cash flows for the six months ended March 31, 2024 include changes in right-of-use assets and operating lease liabilities of $7.9 million and $4.6 million, respectively. For the six months ended March 31, 2023, changes in right-of-use assets and operating lease liabilities were $4.3 million and $3.7 million, respectively. During the three and six months ended March 31, 2024, operating lease expense was $3.9 million and $7.9 million, respectively. Cash payments for amounts included in the measurement of operating lease liabilities were $3.6 million and $7.3 million for the three and six months ended March 31, 2024, respectively. During the three and six months ended March 31, 2023, operating lease expense was $4.1 million and $8.2 million, respectively. Cash payments for amounts included in the measurement of operating lease liabilities were $4.0 million and $7.6 million for the three and six months ended March 31, 2023, respectively. As of March 31, 2024, the weighted-average remaining lease term was 15.3 years and the weighted-average discount rate was 6.5%.
|
Related party transactions |
6 Months Ended |
---|---|
Mar. 31, 2024 | |
Related Party Transactions [Abstract] | |
Related party transactions | Related party transactions During the three months ended March 31, 2024 and 2023, the Company purchased raw materials from a related party in the amount of $1.5 million and $1.5 million, respectively. During the six months ended March 31, 2024 and 2023, the purchases of raw materials from a related party were $2.8 million and $3.5 million, respectively. During the three and six months ended March 31, 2024, the Company had revenues from the related party in the amount of $3.2 million and $5.6 million, respectively. During the three and six months ended March 31, 2023, the Company generated revenues from the related party totaling $2.2 million and $2.6 million, respectively. As of March 31, 2024, payable balances and receivable balances with the related party were $0.3 million and $1.0 million, respectively. Receivable balances with the related party were $1.7 million as of September 30, 2023. Payable balances with the related parties were immaterial as of September 30, 2023.
|
Income taxes |
6 Months Ended |
---|---|
Mar. 31, 2024 | |
Income Tax Disclosure [Abstract] | |
Income taxes | Income taxesIn determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date profit or loss, adjusted for discrete items arising in that quarter. For the three and six months ended March 31, 2024, the Company recorded provisions for income taxes of $0.3 million and $0.5 million, respectively. For the three and six months ended March 31, 2023, the Company recorded provisions for income taxes of $0.7 million and $0.8 million, respectively. |
Common stock |
6 Months Ended |
---|---|
Mar. 31, 2024 | |
Equity [Abstract] | |
Common stock | Common stock As of March 31, 2024, the Company had reserved sufficient shares of common stock, with a par value of $0.00001 per share, for issuance upon exercise of outstanding stock options. Each share of common stock is entitled to one vote. The holders of shares of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors.
|
Stock-based compensation |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | Stock-based compensation The Company grants stock-based awards, consisting of stock options and restricted stock, to its employees, certain non-employee consultants and certain members of its board of directors. The Company measures stock-based compensation expense for restricted stock and stock options granted to its employees and directors on the date of grant and recognizes the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company measures stock-based compensation expense for restricted stock and stock options granted to non-employee consultants on the date of grant and recognizes the corresponding compensation expense of those awards over the period in which the related services are received. The Company adjusts for actual forfeitures as they occur. 2018 Equity Incentive Plan On September 26, 2018, the board of directors adopted the 2018 Equity Incentive Plan (the “2018 Plan”) as a successor to the 2013 Stock Plan (the “2013 Plan”). Any shares subject to outstanding awards under the 2013 Plan that are canceled or repurchased subsequent to the 2018 Plan’s effective date are returned to the pool of shares reserved for issuance under the 2018 Plan. Awards granted under the 2018 Plan may be non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, and performance units. Inducement Equity Incentive Plan On August 22, 2023, the board of directors adopted an inducement equity incentive plan (the “Inducement Plan”). The maximum aggregate number of shares that may be issued under the Inducement Plan is 700,000 of the Company's common stock. The Inducement Plan permits the grant of non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares. The shares issuable under the Inducement Plan are registered pursuant to a registration statement on Form S-8 filed with the Securities and Exchange Commission on August 25, 2023. Restricted Stock Units Restricted stock consists of restricted stock unit awards (“RSUs”) which have been granted to employees and non-employee directors. The value of an RSU award is based on the Company’s stock price on the date of grant. Employee grants generally vest over four years and non-employee director grants generally vest over one year. Forfeitures of RSUs are recognized as they occur. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. Activity with respect to the Company’s restricted stock units during the six months ended March 31, 2024 was as follows:
As of March 31, 2024, there was $69.6 million of total unrecognized compensation cost related to these awards that is expected to be recognized over a weighted average period of 2.7 years. The total grant date fair value of RSUs awarded during the six months ended March 31, 2024 was $31.4 million. Performance Stock Units Performance stock unit awards (“PSUs”) granted to certain employees will vest upon achievement of operational milestones related to the Wilsonville facility, and to Company executives will vest upon achievement of revenue, gross profit and cash balance metrics as determined by the board of directors, and to certain non-employee consultants will vest upon achievement of operational milestones. Stock compensation expense for PSUs is recorded over the vesting period based on the grant date fair value of the awards and probability of the achievement of specified performance targets. The grant date fair value is equal to the closing share price of the Company’s common stock on the date of grant. For employees, PSUs generally vest over a to three-year service period following the grant date, provided that the recipient is a Company employee at the time of vesting and the performance targets applicable to each award are achieved. For non-employees, PSUs generally vest over a to three-year service period following the grant date, provided that the performance targets applicable to each award are achieved. The percentage of PSUs that vest will depend on the achievement of specified performance targets at the end of the performance period and can range from 0% to 150% of the number of units granted. Any PSUs that are unvested at the end of the performance period are forfeited. Forfeitures of PSUs are recognized as they occur. Activity under the PSUs during the six months ended March 31, 2024 is summarized below:
As of March 31, 2024, the unrecognized compensation costs related to these awards was $23.2 million based on the maximum achievement of the performance targets. The Company expects to recognize those costs over a weighted average period of 1.5 years. The total grant date fair value of PSUs awarded during the six months ended March 31, 2024 was $11.4 million. Options Options are generally granted to employees and were granted to non-employee directors until FY 2020. Stock options entitle the holder to purchase, at the end of the vesting term, a specified number of shares of Company common stock at an exercise price per share equal to the closing market price of the common stock on the date of grant. Stock options have a contractual life from the date of the grant and a vesting schedule as established by the board of directors. The maximum term of stock options granted under the 2018 Plan is 10 years and the awards generally vest over a four-year period. Forfeitures of options are recognized as they occur. The fair value of each service based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company has not granted any stock options during the three and six months ended March 31, 2024 or 2023. Options activity during the six months ended March 31, 2024 is summarized below:
As of March 31, 2024, the unrecognized compensation costs related to these awards was $0.5 million. The Company expects to recognize those costs over a weighted average period of 1.2 years. The Company did not grant any options during the six months ended March 31, 2024. Performance Stock Options On September 1, 2020, the board of directors approved the implementation of a revised annual equity award program for executive officers, senior level employees and consultants to be granted as performance-based stock options ("PSOs") under the 2018 Plan. The PSOs issued to executive officers and senior level employees vested in prior years. The number of PSOs ultimately earned under the awards to a consultant is calculated based on the achievement of certain operational milestones. The maximum term of performance stock options granted under the 2018 Plan is 10 years for both employees and non-employees. The awards generally vest over a two-year period for executive officers and senior level employees. Awards to non-employees generally vest over a five-year period. The provisions of the PSOs are considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the Black-Scholes method to calculate the fair value at the grant date without regard to the vesting condition and will recognize compensation cost for the options that are expected to vest. Forfeitures of PSOs are recognized as they occur. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. As of March 31, 2024, the Company determined that 30,000 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program. Activity under the PSOs during the six months ended March 31, 2024 is summarized below:
As of March 31, 2024, the unrecognized compensation costs related to these awards was $0.2 million. The Company expects to recognize those costs over a weighted average period of 1.1 years. Total stock-based compensation expense/(credit) recognized was as follows:
During the three and six months ended March 31, 2023, stock-based compensation decreased primarily as a result of departing employee share forfeitures, and a stock-based credit related to a business combination due to non-achievement of a performance condition. An immaterial amount of stock-based compensation was capitalized to inventories attributable to employees who support the manufacturing of the Company's products for the three and six months ended March 31, 2024 and 2023. An immaterial amount of stock-based compensation was capitalized to property and equipment related to capitalized software development costs for the three and six months ended March 31, 2024. The stock-based compensation of $0.2 million and $0.4 million was capitalized to property and equipment related to the capitalized software development costs for the three and six months ended March 31, 2023. 2018 Employee Stock Purchase Plan On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"). The number of shares reserved for issuance under the 2018 ESPP upon approval was 275,225 shares of the Company’s common stock, and it increases automatically on the first day of each fiscal year, following the fiscal year in which the 2018 ESPP became effective, by a number equal to the least of 249,470 shares, 1% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The number of shares reserved for issuance at March 31, 2024 was as follows:
Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods begin in February and August of each year, except the initial offering period which commenced with the initial public offering in October 2018 and ended on August 20, 2019. Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first trading day of the offering period or 85% of the fair market value of the Company’s common stock on the last trading day of the offering period. During the three and six months ended March 31, 2024 ESPP expenses of $0.5 million and $0.8 million, respectively was recognized. During the three and six months ended March 31, 2023, activity under the 2018 ESPP was immaterial. 401(k) Savings Plan During 2018, the Company adopted a 401(k) savings plan for the benefit of its employees. In January 2022, the Company modified its plan to include an employer matching contribution. The Company is required to make matching contributions to the 401(k) plan equal to 50% of the first 6% of wages deferred by each participating employee. The Company incurred expenses for employer matching contributions of $0.7 million and $1.4 million for the three and six months ended March 31, 2024, respectively. The Company incurred expenses for employer matching contributions of $0.7 million and $1.4 million for the three and six months ended March 31, 2023, respectively. Abveris Acquisition At September 30, 2022, management determined that the achievement of the performance condition relating to the equity awards granted in connection with the Abveris acquisition awards was probable, and cumulative stock-based compensation expense of $9.9 million was recognized during the year ended September 30, 2022. At December 31, 2022, management determined that the performance condition was not achieved, and therefore the cumulative stock-based compensation expense recognized to date was reversed, resulting in a reduction of stock compensation expense of $9.9 million in the three months ended December 31, 2022.
|
Net loss per share attributable to common stockholders |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss per share attributable to common stockholders | Net loss per share attributable to common stockholders The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:
The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:
|
Geographic, product and industry information |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Geographic, product and industry information | Geographic, product and industry information The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia New Zealand, Thailand and Taiwan.
The table below sets forth revenues by products.
The table below sets forth revenues by industry.
|
2023 Restructuring and other costs |
6 Months Ended |
---|---|
Mar. 31, 2024 | |
Restructuring and Related Activities [Abstract] | |
2023 Restructuring and other costs | 2023 Restructuring and other costs On May 3, 2023, the Company’s Board of Directors approved a strategic restructuring plan to reduce costs, build a leaner organization and increase operating efficiencies. The restructuring plan included a reduction in force which affected approximately 270 employees worldwide, representing approximately 25% of the Company’s total workforce. The majority of these employees separated from the Company by September 30, 2023. The reduction in force is subject to local regulatory requirements. Furthermore, as part of the plan the Company removed the duplication of synthetic biology production across its South San Francisco, California and Wilsonville, Oregon facilities. The plan was implemented beginning in May 2023 and was substantially completed by the end of fiscal year 2023. Total restructuring and other costs of $16.2 million was incurred by the Company during the year ended September 30, 2023 and included employee severance and related benefit costs of $8.5 million, restructuring and non-restructuring related impairment of property and equipment of $6.8 million, and other costs associated with restructuring of $0.9 million.
|
Pay vs Performance Disclosure - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Pay vs Performance Disclosure | ||||
Net loss attributable to common stockholders | $ (45,492) | $ (59,156) | $ (88,500) | $ (100,980) |
Insider Trading Arrangements |
3 Months Ended | 6 Months Ended |
---|---|---|
Mar. 31, 2024
shares
|
Mar. 31, 2024
shares
|
|
Trading Arrangements, by Individual | ||
Non-Rule 10b5-1 Arrangement Adopted | false | |
Rule 10b5-1 Arrangement Terminated | false | |
Non-Rule 10b5-1 Arrangement Terminated | false | |
William Banyai [Member] | ||
Trading Arrangements, by Individual | ||
Material Terms of Trading Arrangement | On February 26, 2024, William Banyai, the Company's Senior Vice President of Advanced Development and General Manager of Data Storage, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). Dr. Banyai's 10b5-1 Plan provides for the potential sale of up to 279,027 shares of the Company’s common stock and will expire on the earlier of May 30, 2025 and the date when all shares under the 10b5-1 Plan are sold.
|
|
Name | William Banyai | |
Title | Senior Vice President of Advanced Development and General Manager of Data Storage | |
Rule 10b5-1 Arrangement Adopted | true | |
Adoption Date | February 26, 2024 | |
Arrangement Duration | 459 days | |
Aggregate Available | 279,027 | 279,027 |
Summary of significant accounting policies (Policies) |
6 Months Ended |
---|---|
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Basis of presentation and use of estimates | Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2023 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 21, 2023. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2023 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and six months ended March 31, 2024 are not necessarily indicative of the results expected for the full year ending September 30, 2024 or any interim period. The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation.
|
Allowance for Credit Losses | Allowance for Credit Losses The Company maintains an allowance for credit losses for expected uncollectible accounts receivable and contract assets, which is recorded as an offset to accounts receivable or contract assets and provisions for credit losses are recorded in general and administrative expense in the consolidated statements of income. Under the application of Accounting Standards Codification (“ASC”) Topic 326-20, Financial Instruments—Credit Losses (“ASC 326”), the allowance for current expected credit losses is based on a review of customer accounts and considers historical credit loss information that is adjusted for current economic and business conditions and anticipated future economic events that may impact collectability. In developing its expected credit loss estimate, the Company evaluated the appropriate grouping of accounts receivable and contract assets based upon its evaluation of risk characteristics, including consideration of region and industries of the customers. The allowance for credit losses is reviewed on a quarterly basis to assess the adequacy of the allowance.
|
Short-term investments | Short-term investments The Company invests in various types of securities, including United States government, commercial paper, and corporate debt securities. The Company classifies its investments as available-for-sale and records them at fair value based upon market prices at period end. For available-for-sale debt securities in an unrealized loss position, the Company evaluates whether a current expected credit loss exists based on available information relevant to the credit rating of the security, current economic conditions and reasonable and supportable forecasts. The allowance for credit loss is recorded in other income (expense), net, on the consolidated statements of income, not to exceed the amount of the unrealized loss. Any excess unrealized loss other than the credit loss is recognized in accumulated other comprehensive income or loss in the stockholders' equity section of the consolidated balance sheets. The cost of securities sold is based on the specific identification method and realized gains and losses are included in other income (expense), net. Dividend and interest income are recognized when earned. The Company may sell these securities at any time for use in current operations.
|
Revenue | Revenue The Company had contract assets of $2.7 million and contract liabilities of $2.5 million as of March 31, 2024. The Company had contract assets of $2.8 million and contract liabilities of $3.0 million as of September 30, 2023. For the three and six months ended March 31, 2024, the Company recognized revenue of $0.9 million and $2.2 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period. For the three and six months ended March 31, 2023, the Company recognized revenue of $1.4 million and $2.7 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period. In addition, for all periods presented, there was no revenue recognized in a reporting period from performance obligations satisfied in previous periods. The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of March 31, 2024 was $5.9 million. The Company expects to recognize revenue over the next twelve months relating to performance obligations unsatisfied as of March 31, 2024. Based on the nature of the Company's contracts with customers, which are recognized over a term of less than 12 months, the Company has elected to use the practical expedient whereby costs to obtain a contract are expensed as they are incurred. The Company states its revenues net of any taxes collected from customers that are required to be remitted to various government agencies. The amount of taxes collected from customers and payable to governmental entities is included on the balance sheet as part of “Accrued expenses and other current liabilities.”
|
Recent accounting pronouncements | Recent accounting pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s ASC. The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations. Recent accounting pronouncements adopted In June 2016, FASB issued ASU No. 2016-13 “Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments” and has since modified the standard with several ASUs (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets. The ASU replaced previous incurred loss impairment guidance and established a single expected credit losses allowance framework for financial assets carried at amortized cost. It also eliminated the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses. On October 1, 2023, the Company adopted this standard using a modified retrospective approach, which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption and, accordingly, recorded a net increase of $0.1 million to accumulated deficit as of the beginning of fiscal 2024. In connection with the adoption of Topic 326, the Company made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. Recently issued accounting pronouncement not yet adopted In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740)". The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The standard is not expected to have a material impact to the Company's condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-08 "Segment Reporting (Topic 280)". The amendments in this ASU improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The standard is not expected to have a material impact to the Company's condensed consolidated financial statements. The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.
|
Summary of significant accounting policies (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Cash, Cash Equivalents and Restricted Cash | The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows:
|
Fair value measurement (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Cash and Cash Equivalents | The following table sets forth the cash and cash equivalents, short-term investments and equity securities as of March 31, 2024:
The following table sets forth the cash and cash equivalents, short-term investments and equity securities as of September 30, 2023:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Debt Securities Available-for-Sale | The following table sets forth the cash and cash equivalents, short-term investments and equity securities as of March 31, 2024:
The following table sets forth the cash and cash equivalents, short-term investments and equity securities as of September 30, 2023:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis | As of March 31, 2024, financial assets and liabilities measured and recognized at fair value are as follows:
As of September 30, 2023, financial assets and liabilities measured and recognized at fair value are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation | The following table provides a reconciliation of beginning and ending balances of the Level 3 financial assets during the three months ended March 31, 2024:
|
Balance sheet components (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Related Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Inventories | Inventories consist of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Property, Plant and Equipment | Property and Equipment, net consists of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Other Current Liabilities | The other current liabilities consist of the following:
|
Goodwill and intangible assets (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Goodwill balance | The goodwill balance is presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Intangible Assets | The intangible assets balances are presented below:
|
Commitments and contingencies (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Supplemental Balance Sheet Information Relating to Companies Operating Lease | Supplemental balance sheet information related to the Company’s operating leases as of March 31, 2024 is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Future Minimum Rental Payments for Operating Leases | Future minimum lease payments under all non-cancelable operating leases that have commenced as of March 31, 2024 are as follows:
|
Stock-based compensation (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Nonvested Restricted Stock Units Activity | Activity with respect to the Company’s restricted stock units during the six months ended March 31, 2024 was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Nonvested Performance-based Units Activity | Activity under the PSUs during the six months ended March 31, 2024 is summarized below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Activity Under Option and Performance Stock Options | Options activity during the six months ended March 31, 2024 is summarized below:
Activity under the PSOs during the six months ended March 31, 2024 is summarized below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock-Based Compensation Expenses | Total stock-based compensation expense/(credit) recognized was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Stock Option Valuation Assumptions | The number of shares reserved for issuance at March 31, 2024 was as follows:
|
Net loss per share attributable to common stockholders (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders | The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Calculation of Diluted Net Loss Per Share | The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:
|
Geographic, product and industry information (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Revenue by Geographic Region | The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia New Zealand, Thailand and Taiwan.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Revenue by Product | The table below sets forth revenues by products.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Revenue by Industry | The table below sets forth revenues by industry.
|
The Company (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Accumulated deficit | $ 1,121,682 | $ 1,033,034 |
Cash, cash equivalents, and short-term investments | $ 293,300 |
Summary of significant accounting policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
---|---|---|---|---|
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 243,348 | $ 286,470 | ||
Restricted cash, non-current | 2,868 | 2,811 | ||
Total cash, cash equivalents and restricted cash | $ 246,216 | $ 289,281 | $ 317,561 | $ 380,259 |
Summary of significant accounting policies - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Jan. 01, 2024 |
Sep. 30, 2023 |
|
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||
Accounts receivable, allowance for credit loss | $ 700 | $ 700 | ||||
Contract with customer, asset, after allowance for credit loss | 2,700 | 2,700 | $ 2,800 | |||
Contract with customer, liability | 2,500 | 2,500 | 3,000 | |||
Contract with customer, liability, revenue recognized | 900 | $ 1,400 | 2,200 | $ 2,700 | ||
Revenue, remaining performance obligation, amount | 5,900 | 5,900 | ||||
Accumulated deficit | $ (1,121,682) | $ (1,121,682) | $ (1,033,034) | |||
Cumulative Effect, Period of Adoption, Adjustment | ||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||
Accumulated deficit | $ (100) |
Fair value measurement - Narrative (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Equity securities, FV-NI, cost | $ 3,711 | $ 3,711 |
Equity ownership, excluding consolidated entity and equity method investee, percentage | 15.00% | |
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value | $ 3,700 | |
Convertible Note | Convertible Notes Payable | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Equity securities, FV-NI, cost | $ 3,500 | |
Debt instrument, interest rate, stated percentage | 4.00% | |
Prepaid Expenses and Other Current Assets | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Interest receivable | $ 1,100 | $ 1,200 |
Fair value measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Details) $ in Thousands |
6 Months Ended |
---|---|
Mar. 31, 2024
USD ($)
| |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Balance as of September 30, 2023 | $ 3,711 |
Change in fair value | 0 |
Additions during the year | 0 |
Balance as of March 31, 2024 | $ 3,711 |
Fair value, liability, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income | Change In Fair Value Of Contingent Consideration And Indemnity Holdback |
Equity Method Investments | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Balance as of September 30, 2023 | $ 3,711 |
Change in fair value | 0 |
Additions during the year | 0 |
Balance as of March 31, 2024 | $ 3,711 |
Balance sheet components - Inventory (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Balance Sheet Related Disclosures [Abstract] | ||
Raw materials | $ 21,788 | $ 27,024 |
Work-in-process | 2,814 | 1,113 |
Finished goods | 5,774 | 3,926 |
Total inventories | $ 30,376 | $ 32,063 |
Balance sheet components - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Balance Sheet Related Disclosures [Abstract] | ||||
Depreciation | $ 7.0 | $ 5.7 | $ 13.9 | $ 9.9 |
Balance sheet components - Other current liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Balance Sheet Related Disclosures [Abstract] | ||
Income and other taxes payable | $ 2,105 | $ 4,374 |
Contract liabilities | 2,542 | 2,999 |
Other current liabilities | 792 | 430 |
Other current liabilities | $ 5,439 | $ 7,803 |
Goodwill and intangible assets - Summary of Goodwill (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Goodwill [Roll Forward] | ||
Balance at beginning of year | $ 85,811 | $ 85,811 |
Balance at end of year | $ 85,811 | $ 85,811 |
Goodwill and intangible assets - Goodwill (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Goodwill and Intangible Assets Disclosure [Abstract] | ||||
Total amortization expense related to intangible assets | $ 1.3 | $ 1.3 | $ 2.6 | $ 2.7 |
Commitments and contingencies - Operating Leases On Balance Sheet (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Assets: | ||
Operating lease right-of-use assets | $ 63,666 | $ 71,531 |
Current liabilities: | ||
Current portion of operating lease liability | 14,621 | 14,896 |
Noncurrent liabilities: | ||
Operating lease liability, net of current portion | $ 74,804 | $ 79,173 |
Commitments and contingencies - Minimum Rental Payments (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Sep. 30, 2023 |
---|---|---|
Commitments and Contingencies Disclosure [Abstract] | ||
Remainder of 2024 | $ 7,336 | |
2025 | 14,814 | |
2026 | 13,885 | |
2027 | 8,371 | |
2028 | 8,471 | |
Thereafter | 88,014 | |
Total minimum lease payments | 140,891 | |
Less: imputed interest | (51,466) | |
Total operating lease liabilities | 89,425 | |
Less: current portion | (14,621) | $ (14,896) |
Operating lease liability, net of current portion | $ 74,804 | $ 79,173 |
Commitments and contingencies - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Commitments and Contingencies Disclosure [Abstract] | ||||
Change in right-of-use asset | $ 7.9 | $ 4.3 | ||
Change in operating lease liabilities | 4.6 | 3.7 | ||
Operating lease expense | $ 3.9 | $ 4.1 | 7.9 | 8.2 |
Operating lease payments | $ 3.6 | $ 4.0 | $ 7.3 | $ 7.6 |
Lease weighted-average remaining lease term | 15 years 3 months 18 days | 15 years 3 months 18 days | ||
Lease weighted average discount rate | 6.50% | 6.50% |
Related party transactions - (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Sep. 30, 2023 |
|||
Related Party Transaction [Line Items] | |||||||
Raw materials purchased from related party investor | $ 1,500 | $ 1,500 | $ 2,800 | $ 3,500 | |||
Revenue | [1] | 75,302 | 60,180 | 146,800 | 114,423 | ||
Accounts receivable, net | 35,993 | 35,993 | $ 44,064 | ||||
Related Party | |||||||
Related Party Transaction [Line Items] | |||||||
Revenue | 3,200 | $ 2,200 | 5,600 | $ 2,600 | |||
Accounts payable | 300 | 300 | |||||
Accounts receivable, net | $ 1,000 | $ 1,000 | |||||
Related party consideration | $ 1,700 | ||||||
|
Income taxes (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Income Tax Disclosure [Abstract] | ||||
Income tax benefit | $ 345 | $ 676 | $ 465 | $ 752 |
Common stock (Details) |
6 Months Ended | |
---|---|---|
Mar. 31, 2024
vote
$ / shares
|
Sep. 30, 2023
$ / shares
|
|
Equity [Abstract] | ||
Common stock, par value (in usd per share) | $ / shares | $ 0.00001 | $ 0.00001 |
Number of votes per share | vote | 1 |
Stock-based compensation - Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock based compensation expense | $ 13,824 | $ 10,259 | $ 24,844 | $ 7,934 |
Cost of revenues | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock based compensation expense | 1,049 | 1,469 | 1,973 | 2,612 |
Research and development | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock based compensation expense | 3,376 | 3,090 | 6,214 | 7,508 |
Selling, general and administrative | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock based compensation expense | $ 9,399 | $ 5,700 | $ 16,657 | $ (2,186) |
Stock-based compensation - Reserved For Issuance (Details) shares in Thousands |
6 Months Ended |
---|---|
Mar. 31, 2024
shares
| |
Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding [Roll Forward] | |
Beginning balance (in shares) | 539 |
Additional shares authorized (in shares) | 249 |
Shares issued during the period (in shares) | (124) |
Ending balance (in shares) | 664 |
Stock-based compensation - Abveris Acquisition (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Sep. 30, 2022 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock based compensation expense (reduction) | $ 13,824 | $ 10,259 | $ 24,844 | $ 7,934 | |
Abveris | Performance Shares | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock based compensation expense (reduction) | $ 9,900 |
Net loss per share attributable to common stockholders - Computation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Numerator: | ||||
Net loss attributable to common stockholders | $ (45,492) | $ (59,156) | $ (88,500) | $ (100,980) |
Denominator: | ||||
Weighted average shares used in computing net loss per share, basic (in shares) | 57,779 | 56,777 | 57,637 | 56,608 |
Weighted average shares used in computing net loss per share, diluted (in shares) | 57,779 | 56,777 | 57,637 | 56,608 |
Net loss per share attributable to common stockholders—basic (in usd per share) | $ (0.79) | $ (1.04) | $ (1.54) | $ (1.78) |
Net loss per share attributable to common stockholders, diluted (in usd per share) | $ (0.79) | $ (1.04) | $ (1.54) | $ (1.78) |
Geographic, product and industry information - Geographic Region (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Segment Reporting Information [Line Items] | ||||||
Revenue | [1] | $ 75,302 | $ 60,180 | $ 146,800 | $ 114,423 | |
Americas | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 45,873 | 34,925 | 89,832 | 68,571 | ||
EMEA | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 22,263 | 18,780 | 43,483 | 35,111 | ||
APAC | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | $ 7,166 | $ 6,475 | $ 13,485 | $ 10,741 | ||
|
Geographic, product and industry information - By Product (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Segment Reporting Information [Line Items] | ||||||
Revenue | [1] | $ 75,302 | $ 60,180 | $ 146,800 | $ 114,423 | |
Synthetic genes | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 22,356 | 18,011 | 42,083 | 34,186 | ||
Oligo pools | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 3,940 | 3,315 | 8,129 | 7,015 | ||
DNA libraries | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 3,531 | 2,826 | 6,470 | 4,662 | ||
Antibody discovery | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 4,701 | 7,034 | 9,927 | 15,205 | ||
NGS tools | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | $ 40,774 | $ 28,994 | $ 80,191 | $ 53,355 | ||
|
Geographic, product and industry information - By Industry (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|||
Segment Reporting Information [Line Items] | ||||||
Revenue | [1] | $ 75,302 | $ 60,180 | $ 146,800 | $ 114,423 | |
Industrial chemicals/materials | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 20,264 | 14,410 | 36,542 | 27,985 | ||
Academic research | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 13,722 | 11,120 | 27,495 | 21,135 | ||
Healthcare | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | 40,934 | 33,764 | 81,815 | 63,777 | ||
Food/agricultural | ||||||
Segment Reporting Information [Line Items] | ||||||
Revenue | $ 382 | $ 886 | $ 948 | $ 1,526 | ||
|
2023 Restructuring and other costs - Narrative (Details) - 2023 Restructuring Plan $ in Millions |
12 Months Ended | |
---|---|---|
May 03, 2023
employee
|
Sep. 30, 2023
USD ($)
|
|
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related cost, expected number of positions eliminated | employee | 270 | |
Restructuring and related cost, number of positions eliminated, period percent | 25.00% | |
Total | $ 16.2 | |
Severance and related benefit costs | ||
Restructuring Cost and Reserve [Line Items] | ||
Total | 8.5 | |
Asset Impairments | ||
Restructuring Cost and Reserve [Line Items] | ||
Total | 6.8 | |
Other associated costs | ||
Restructuring Cost and Reserve [Line Items] | ||
Total | $ 0.9 |
T"U.H (6PN*!1U:(BCWA.QR.,HNR?H;R4X%IP:7A*=,Y",S12: M!#N]1F"L XUV.Q61<_JDS !80S8]KQXMWEF4QL15EIWMUY&P/S$&HI[[-53# M
[0,:M.64S5Y KX;3Y/)='+,L_'M5]P2LW+?CK\G
M6?M]LI>LYY!NK<[J^8*O1_&)*ERM<+G#I#_C#X+5:C298\ZMGFD?0H$A,1JN74Y",A>D@
MM]J%^4)0(K/GY]/18KE\$<4\'=75R]$"Q@91A_%Y'F+^XON"Z_=PS=&,?Y/;
MG&4$?-N4K+S'IL/_5A9VVX?E$=DFR>D(P>_O'F9\G'N>\!?*GUV,7P):I9I]
MX+/%>-G<&/D^WI _QKL_9!XV;=]IES]5@B'SH67S\<5CEMW6IMGD83@1H'*(V_)_QFU^:/CU$18->YV=
M_ZE?I*>@7<,WS>EG9RJU<8_4]!R1W'M";0[X'BRFD<-O(@W-);1J.3[_T_C8
M#\5GO=_Y"V$V_K\9K#\Z=^$G__9N^P\3U^'_!+K7PW];P*\-'=@JD6'I9'QQ
M?A+JN/GB=.7_:V"M'892?YD+#NZG%_ \T]@$QR^DH/TWDJO_ E!+ P04
M" "Q@:)8A^,VNOL" "#" &0 'AL+W=O&$KJ(K@4'-#+1,-N@CWB;3A'XSJ-'T
MP G0;@!A;<-4CM#41(!/:')A X)6@75,<:%V@U)=^XFT4[AFI#60_)V<^("D
M"2=)JM.@%4*K'4[A*Q54:LG1!,7'M8.G9-+J%R0&
E?L"R
M9\)L]%(O,4D?6TE.K#I)*S_K9*6S
MA&W78GJO9;^5EE:WU!PPP6Z@R,)8U00(VZKA)Z%^3WL=._.F]BQJCV(3GB#_7MKT;[^P#]_#B68P7_3_B
MXW,)-V&C>DN=7$,U.BKPP##C$V1<.#V$:W^E'1X1@6SQ:I/&"V!_K;6[6W@#
MAW?@_&]02P,$% @ L8&B6"1X9FD@! 90D !D !X;"]W;W)K1HF!#PS>O^O%<7BUK4%W-*IKB:X^GL$-O